Matching articles for "Izervay"
Valeda Light Delivery System for Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • January 20, 2025; (Issue 1720)
The FDA has authorized use of the Valeda Light
Delivery System (LumiThera), a multiwavelength
photobiomodulation (PBM) device, to improve visual
acuity in patients with dry age-related macular
degeneration...
The FDA has authorized use of the Valeda Light
Delivery System (LumiThera), a multiwavelength
photobiomodulation (PBM) device, to improve visual
acuity in patients with dry age-related macular
degeneration (AMD) who have best-corrected visual
acuity (BCVA) of 20/32 to 20/70.
Drugs for Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • January 6, 2025; (Issue 1719)
Age-related macular degeneration (AMD) has two
major forms: dry or non-neovascular (~90% of
patients) and wet or neovascular (~10% of...
Age-related macular degeneration (AMD) has two
major forms: dry or non-neovascular (~90% of
patients) and wet or neovascular (~10% of patients).
Avacincaptad Pegol (Izervay) for Geographic Atrophy in Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • January 22, 2024; (Issue 1694)
The FDA has approved the complement C5 inhibitor
avacincaptad pegol (Izervay – Iveric) for intravitreal
treatment of geographic atrophy (GA) secondary
to age-related macular degeneration...
The FDA has approved the complement C5 inhibitor
avacincaptad pegol (Izervay – Iveric) for intravitreal
treatment of geographic atrophy (GA) secondary
to age-related macular degeneration (AMD).
Avacincaptad pegol is the second complement
inhibitor to be approved in the US for this indication;
pegcetacoplan (Syfovre), a complement C3 and C3b
inhibitor, was approved earlier.